In this RCT, patients with an UGI bleed and high risk of recurrent bleeding (active bleeding, visible vessel, or adherent clot) recieved either high dose PPI (80mg bolus, then 8mg/hr for 3 days) or standard dose PPI (40mg bolus qday for 3 days). There was no difference between the groups in re-bleeding or units of transfused blood, but the standard dose group was much more likely to have a LOS <5 days. This indicates that standard dose PPI is not only clinically equivalent to high dose PPI therapy in reducing re-bleeding in high risk patients, but that it is also logistically preferable (abstract), as an accompanying editorialist agrees (editorial)
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
This large trial of patients with a relative contraindication for enteral feeds were randomized to early TPN or usual care. There were no differences in the groups in 60 day mortality or LOS, but those on TPN did have a shorter time ventilated and less muscle/fat loss. It is unclear based on this trial if […]